Comerica Bank Tower, the Second Tallest Skyscraper in Dallas, Selects Boingo Wireless to Deploy Reliable Cellular Service and Public Safety Network
BNGO(NASDAQ:BNGO) FRISCO, Texas--(BUSINESS WIRE)--Boingo’s end-to-end cellular solution brings reliable connectivity to Dallas’ Comerica Bank Tower.
Hollywood Burbank Airport Selects Boingo Wireless to Deploy Industry-Leading Converged 5G and Wi-Fi 7 Network, Redefining Connectivity for Passengers and Operations
BNGOLOS ANGELES--(BUSINESS WIRE)--Major Los Angeles area airport taps Boingo for secure, seamless cellular and Wi-Fi that connects passengers and operations.
Bionano Announces Publication Showing Utility of Optical Genome Mapping in Clinical Research of Infant & Toddler T-ALL
BNGOSAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication from a team led by Manon Delafoy from the Institut Necker Enfants Malades (INEM) and colleagues from multiple French pediatric hematology centers showing how optical genome mapping (OGM) can be used to detect oncogenic structural variants (SVs) in clinical research of infant and toddler T-cell acute lymphoblastic leukemia (T-ALL). The publication shows that OGM can reveal distinct genetic drivers and prognostic subgroups that conventional cytogenetics failed to identify in a retrospective, national cohort of 27 T-ALL cases of infants and toddlers (<3 years) as part of a combined workflow of targeted sequencing, OGM, and RNA sequencing. Infants and toddlers can be a difficult segment of the population to analyze because their cancers are rare. The study conclusions support using OGM as a complementary tool to conventional assays to help accurately stratify sam
Maxim Group Upgrades Bionano Genomics to Buy, Announces $8 Price Target
BNGOBionano Genomics Lowers FY2025 Sales Guidance from $29.00M-$32.00M to $26.00M-$30.00M vs $33.43M Est
BNGOBionano Genomics Sees Q2 Sales $6.300M-$6.800M vs $7.02M Est
BNGOBionano Genomics Q1 EPS $(1.15) Beats $(3.02) Estimate, Sales $6.50M Beat $6.23M Estimate
BNGOBionano Genomics Q1 Sales $6.50M Beat $6.23M Estimate
BNGOA Glimpse of Bionano Genomics's Earnings Potential
BNGOBionano Labs: Intn'l Consortium For Optical Genome Mapping Publishes Expert Recommendations For Integration Of OGM As SOC Cytogenetic Assay For Diagnostic Workflows In Blood Cancers
BNGOBionano Genomics Announces Peer-Reviewed Publication In Genome Research Demonstrating That Optical Genome Mapping Can Be an Accurate, Cost-Effective Method For Detecting And Sizing Large Repeat Expansions, Linked To As Many As 40 Genetic Disorders
BNGOHC Wainwright & Co. Initiates Coverage On Bionano Genomics with Buy Rating, Announces Price Target of $10
BNGOBionano Genomics' Optical Genome Mapping Method Enhances Multiple Myeloma Analysis, Reduces Cell Requirements, Uncovers Additional Genetic Variants, Streamlines Workflow, And Improves Prognostic Risk Evaluation, According To Study Published In The Journal
BNGOScotiabank Maintains Sector Perform on Bionano Genomics, Raises Price Target to $4
BNGOWhat's Next: Bionano Genomics's Earnings Preview
BNGOBionano Genomics Announces A Publication In Genome Research Describing The First Study To Use Optical Genome Mapping To Investigate The Genetic Landscape Of Neural Tube Defects
BNGOBionano Genomics Announces Study In American Journal Of Hematology On Optical Genome Mapping Detecting 16% Chromoanagenesis In AML Cases, Potentially More Sensitive Than Traditional Methods
BNGOBionano Genomics May Offer, Sell Shares Of Common Stock Of Up To $75M From Time To Time
BNGOBionano Announces Publication Of A Case Study From The Shenzhen Maternity And Child Healthcare Hospital, China, Demonstrating The Application Of Optical Genome Mapping In A Protocol For Preimplantation Genetic Testing For Structural Rearrangements
BNGOBionano Preliminary Revenue For Q4 2024 Expected Between $7.9M-$8.1M Despite 25% Decrease; Optical Genome Mapping Systems Increase By 14% To 371 Units; Nanochannel Array Flowcells Sales Rise 1% To 8,058 Units
BNGOBionano Announces Publication From Johns Hopkins School Of Medicine Showing That OGM Outperformed Multiple Cytogenetic Assays In A Study Of Bone And Soft Tissue Tumor Analysis
BNGOLadenburg Thalmann Downgrades Bionano Genomics to Neutral
BNGOBionano Genomics Q3 Sales $6.07M Miss $7.85M Estimate
BNGOBionano Announces $3M Registered Direct Offering Priced At-the-Market under Nasdaq Rules
BNGOThree Publications Demonstrate Bionano's OGM's Utility For Cell And Gene Therapy; Publications Include Niño Jesús University Children's Hospital; Ruhr-University Bochum And Janssen
BNGOBTIG Maintains Buy on Bionano Genomics, Lowers Price Target to $2
BNGOBionano Genomics's Earnings Outlook
BNGOBionano Genomics (NASDAQ:BNGO) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement.
Analysts estimate that Bionano Genomics will report an earnings per share (EPS) of $-0.07.
Bionano Genomics Highlights Peer-Reviewed Publication Of NeuroSCORE Model To Predict, Prioritize Human Genes Contributing To Neurodevelopmental Disease
BNGO